Scarica l'app Stockscreener
6.41
3.55%
0.22
Pre-mercato:
6.62
0.21
+3.28%
Precedente Chiudi:
$6.19
Aprire:
$6.16
Volume 24 ore:
1.79M
Relative Volume:
0.81
Capitalizzazione di mercato:
$1.14B
Reddito:
-
Utile/perdita netta:
$-45.44M
Rapporto P/E:
-18.31
EPS:
-0.35
Flusso di cassa netto:
$-42.28M
1 W Prestazione:
+12.26%
1M Prestazione:
+23.98%
6M Prestazione:
+101.57%
1 anno Prestazione:
+127.30%
Intervallo 1D:
$6.13
$6.48
Intervallo di 1 settimana:
$5.635
$6.48
Portata 52W:
$1.33
$6.48
Compass Therapeutics Inc Stock (CMPX) Company Profile
Nome
Compass Therapeutics Inc
Settore
Industria
Telefono
617-500-8099
Indirizzo
80 GUEST STREET, BOSTON
Confronta CMPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
6.41 | 1.10B | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Canaccord Genuity | Buy |
| 2025-12-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-01 | Ripresa | Raymond James | Outperform |
| 2025-04-02 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Iniziato | Guggenheim | Buy |
| 2025-02-19 | Iniziato | Piper Sandler | Overweight |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Iniziato | Jefferies | Buy |
| 2023-01-27 | Iniziato | Stifel | Buy |
| 2022-05-23 | Ripresa | H.C. Wainwright | Buy |
| 2022-03-15 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-01-19 | Iniziato | B. Riley Securities | Buy |
| 2021-12-22 | Iniziato | Raymond James | Outperform |
| 2021-12-20 | Iniziato | SVB Leerink | Outperform |
| 2021-12-15 | Iniziato | Wedbush | Outperform |
Mostra tutto
Compass Therapeutics Inc Borsa (CMPX) Ultime notizie
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High? - Finviz
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Institution Moves: Is Compass Therapeutics Inc stock a top performer YTD2025 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn
Momentum Shift: Is Compass Therapeutics Inc stock a top performer YTDJuly 2025 Summary & Verified Chart Pattern Signals - baoquankhu1.vn
Weekly Trades: Is Red Cat Holdings Inc a good stock for dollar cost averaging2025 Short Interest & Consistent Profit Trading Strategies - baoquankhu1.vn
SG Americas Securities LLC Has $523,000 Stake in Compass Therapeutics, Inc. $CMPX - MarketBeat
Compass Therapeutics stock hits 52-week high at 6.25 USD By Investing.com - Investing.com Nigeria
Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month HighHere's What Happened - MarketBeat
Compass Therapeutics stock hits 52-week high at 6.25 USD - Investing.com
Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement - MSN
Compass Therapeutics: Exciting Clinical Updates Inbound For 2026, But Don't Get Too Ahead - Seeking Alpha
Compass Therapeutics, Inc. (CMPX): A Bull Case Theory - Finviz
Is Compass Therapeutics Inc. stock a defensive play in 2025Weekly Investment Summary & Reliable Price Breakout Signals - bollywoodhelpline.com
How Compass Therapeutics Inc. stock reacts to global recession fearsJuly 2025 Analyst Calls & Real-Time Volume Analysis - bollywoodhelpline.com
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Assessing Compass Therapeutics (CMPX) Valuation After Strong 1 Year Share Price Performance - Yahoo Finance
Assessing Compass Therapeutics (CMPX) Valuation After A Year Of Strong Share Price Momentum - Sahm
Aug Catalysts: How does Compass Therapeutics Inc perform in inflationary periods2025 Buyback Activity & Risk Managed Trade Strategies - baoquankhu1.vn
Is Compass Therapeutics (CMPX) Quietly Rewriting Its Oncology Strategy With New Commercial and Medical Chiefs? - Yahoo Finance
Compass Therapeutics (NASDAQ:CMPX) Trading Down 6.8%Time to Sell? - MarketBeat
Will Compass Therapeutics’ (CMPX) New Oncology Leaders Redefine Its Path From Pipeline to Commercial Scale? - Sahm
Compass Therapeutics (NASDAQ:CMPX) Sets New 12-Month HighTime to Buy? - MarketBeat
Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development - MSN
Growth Review: Is Compass Therapeutics Inc stock a top pick in earnings seasonJuly 2025 Summary & Community Consensus Trade Alerts - Bộ Nội Vụ
Lifesci Capital Has Strong Estimate for CMPX FY2025 Earnings - Defense World
What is Lifesci Capital's Estimate for CMPX FY2025 Earnings? - MarketBeat
Why Compass Therapeutics Inc. stock could outperform in 2025Market Trend Report & Scalable Portfolio Growth Ideas - Улправда
Will Compass Therapeutics Inc. stock benefit from green energy trendsQuarterly Profit Summary & Low Drawdown Momentum Ideas - ulpravda.ru
Is Compass Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Rallies & Capital Protection Trading Alerts - Улправда
Short Squeeze: Is Compass Therapeutics Inc. stock supported by strong fundamentalsWeekly Trade Review & Daily Volume Surge Signals - ulpravda.ru
Will Compass Therapeutics Inc. stock benefit from commodity prices2025 Fundamental Recap & Weekly Breakout Watchlists - Улправда
Is Compass Therapeutics Inc. stock supported by strong fundamentals2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - Улправда
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a Biotech Powerhouse with 142.77% Upside Potential - DirectorsTalk Interviews
Why analysts remain bullish on Compass Therapeutics Inc. stock2025 Investor Takeaways & Reliable Entry Point Alerts - ulpravda.ru
Is Compass Therapeutics Inc. stock in correction or buying zoneMarket Capitalization Trends & Reinvest for Maximum Compounding Returns - Улправда
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Compass Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Compass Therapeutics details cash runway and pipeline progress - MSN
Compass Therapeutics (NASDAQ:CMPX) Stock Price Up 11.1%What's Next? - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Compass Therapeutics appoints new chief commercial and medical officers By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Compass Therapeutics stock with $12 target - Investing.com Canada
Raymond James reiterates Outperform rating on Compass Therapeutics stock By Investing.com - Investing.com Canada
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Compass Therapeutics reports progress across cancer drug pipeline By Investing.com - Investing.com South Africa
Compass Therapeutics Provides Corporate Update - The Manila Times
Compass Therapeutics reports progress across cancer drug pipeline - Investing.com
CMPXCompass Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Compass Therapeutics Inc Azioni (CMPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):